Elive Biotherapeutics is a pre-clinical Delaware company of accomplished drug developers and synthetic biologists, with a patented first of kind disruptive next-generation in situ Platform. Elive’s platform is a synthetic biology engine inside a microbe for sensing, computing and producing small molecule drugs. Future drugs will be produced inside humans for treatment to dramatically reduce drug toxicity. Using Elive’s in situ platform, an FDA approved anti-cancer drug has now been bioengineered to treat small cell lung cancer which is known for its very poor prognosis. Elive is presently raising USD 0.5 M to conduct a proof of concept in animal models....
Elive Biotherapeutics is a pre-clinical Delaware company of accomplished drug developers and synthetic biologists, with a patented first of kind disruptive next-generation in situ Platform. Elive’s platform is a synthetic biology engine inside a microbe for sensing, computing and producing small molecule drugs. Future drugs will be produced inside humans for treatment to dramatically reduce drug toxicity. Using Elive’s in situ platform, an FDA approved anti-cancer drug has now been bioengineered to treat small cell lung cancer which is known for its very poor prognosis. Elive is presently raising USD 0.5 M to conduct a proof of concept in animal models.
More information

Employees

Shriram Raghavan
Admin
Shriram Raghavan VIce President Cofounded 6 startups in different verticals of life sciences